Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.

Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.

Item
http://www.wikidata.org/entity/Q35583788
Bone metastases: Causes, consequences and therapeutic opportunitiesZoledronic acid effectiveness against breast cancer metastases - a role for estrogen in the microenvironment?Latin-American guidelines for cancer pain management.Chemical and Radiation-Associated Jaw Lesions.Silibinin inhibits prostate cancer cells- and RANKL-induced osteoclastogenesis by targeting NFATc1, NF-κB, and AP-1 activation in RAW264.7 cells.A phase II, multicentre trial evaluating the efficacy of de-escalated bisphosphonate therapy in metastatic breast cancer patients at low-risk of skeletal-related events.Optimising the use of bone-targeted agents in patients with metastatic cancers: a practical guide for medical oncologists.Management of advanced prostate cancer in senior adults: the new landscape.The role of palliative external beam radiation therapy in boney metastases pain management.The critical role of bisphosphonates to target bone cancer metastasis: an overview.Bone-targeted agents in the treatment of bone metastases: RANK outsider or new kid on the block?The use of bisphosphonates in the management of bone involvement from solid tumours and haematological malignancies - a European survey.Persistence with bisphosphonates in patients with metastatic breast cancer: a retrospective database analysis.Synthesis and biological evaluation of bisphosphonate compound labeled with (99m)Tc(CO)3(+).Pathogenesis of medication-related osteonecrosis of the jaw: a comparative study of in vivo and in vitro trials
P2860

Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.

Item
http://www.wikidata.org/entity/Q35583788
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
@ast
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
@en
type
label
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
@ast
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
@en
prefLabel
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
@ast
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P932
P356
P1433
P1476
Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases
@en
P2093
P2860
P304
P31
P356
10.1634/THEONCOLOGIST.2007-0245
P433
P478
P50
P577
P5875
P698
P932